IndiTreat® Tests
Focus on colorectal cancer (CRC)
2cureX has a strategy of focusing on colorectal cancer, the third largest cancer type, with 1.9M new cases every year. This is projected to grow to 3.2M per year in 2040 mainly due to population aging and changes in lifestyle. Current approaches to personalized treatment in CRC are very limited, and this is recognized by oncologists as a burning clinical need as demonstrated in our independent 2022 survey of 140 oncologists in three of our key markets (see our Strategy Deep-Dive here).
The company aims to build a sustainable leading position in this segment through the advantages of being the first entrant, developing superior understanding of the dynamics of this segment, building a portfolio of products focused on specific customer needs and creating customer loyalty as a consequence of the above.
We have launched three CE-marked tests (IndiTreat® Start, Extend and Explore) to support therapy decision-making in metastatic colorectal cancer. At the end of 2022, we announced the start of the development project for a new IndiTreat® product (IndiTreat® Neo) that will support treatment decisions in earlier stages of colorectal cancer, thus expanding the current market opportunity.
IndiTreat® mCRC Start
IndiTreat® mCRC Start test is for patients with newly diagnosed metastatic colorectal cancer (synchronous metastases) or previously treated localized disease with new onset of metastases (metachronous metastases). The aim of drug treatment is to downsize metastases to make them operable, or palliative to extend survival and / or improve quality of life.
To download the product sheet, please go here.
IndiTreat® mCRC Extend
IndiTreat® mCRC Extend is for patients with metastatic colorectal cancer showing tumor progression after at least two previous lines of systemic therapy. The aim of drug treatment in these patients is not curative, but palliative, with the intention to extend survival and/or improve quality of life.
To download the product sheet, please go here.
IndiTreat® mCRC Explore
IndiTreat® mCRC Explore test is for patients with metastatic colorectal cancer showing tumor progression after at least two previous lines of drug therapy. The aim of treatment is palliative, with the intention to extend survival and/or improve quality of life.
To download the product sheet, please go here.
Downloads and more information
To download our brochure, product sheets or the clinical evidence for IndiTreat®, please go here.
For more information, please go to www.inditreat.com.
